These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of the pharmacologist. From neuroleptics to non-neuroleptic antipsychotics]. Costentin J Encephale; 2009 Jan; Suppl 3():S119-22. PubMed ID: 19268181 [No Abstract] [Full Text] [Related]
5. The use of high doses of neuroleptics: the current situation. King DJ Int Clin Psychopharmacol; 1994; 9(2):75-8. PubMed ID: 7914527 [No Abstract] [Full Text] [Related]
6. Typical neuroleptics and increased subcortical volumes. Dean CE Am J Psychiatry; 1999 Nov; 156(11):1843-4. PubMed ID: 10553769 [No Abstract] [Full Text] [Related]
7. Novel pharmacological approaches to the treatment of schizophrenia. Fink-Jensen A Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983 [TBL] [Abstract][Full Text] [Related]
8. [Response to the position of the "Biological Psychiatry" Working Group of the Federal Directors Conference--Association of Executive Physicians of Psychiatry and Psychotherapy Clinics (BDK) e.V]. Aderhold V Psychiatr Prax; 2009 Mar; 36(2):94-5. PubMed ID: 19358097 [No Abstract] [Full Text] [Related]
9. [Treatment strategies of psychotic states using low-dose neuroleptics: immediate and long-term course]. Schmitt L; Lemaire A; Lefranc G; Febrer A; Moron P Ann Med Psychol (Paris); 1988; 146(1-2):119-23. PubMed ID: 2901243 [TBL] [Abstract][Full Text] [Related]
10. Ideal and reality of neuroleptic relapse prevention. Kissling W Br J Psychiatry Suppl; 1992 Oct; (18):133-9. PubMed ID: 1356363 [No Abstract] [Full Text] [Related]
11. Reversible cerebral atrophy: a case report and literature review. Thirugnanasampanthan U; Foster A; Rauch RA Gen Hosp Psychiatry; 2006; 28(5):458-62. PubMed ID: 16950389 [No Abstract] [Full Text] [Related]
13. Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. McClure RK; Phillips I; Jazayerli R; Barnett A; Coppola R; Weinberger DR Psychiatry Res; 2006 Dec; 148(2-3):121-32. PubMed ID: 17097276 [TBL] [Abstract][Full Text] [Related]
14. [Neuroleptics and nicotine]. Erdmann R Psychiatr Prax; 1995 Nov; 22(6):223-7. PubMed ID: 8570751 [TBL] [Abstract][Full Text] [Related]
15. [Preliminary study of schizophrenics with brain atrophy treated with antipsychotic drugs]. Wang XY Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1988 Oct; 21(5):294-6, 319. PubMed ID: 2906857 [No Abstract] [Full Text] [Related]
16. [First and second generation antipsychotics and morphological and neurochemical brain changes in schizophrenia. Review of magnetic resonance imaging and proton spectroscopy findings]. Szulc A Psychiatr Pol; 2007; 41(3):329-38. PubMed ID: 17900049 [TBL] [Abstract][Full Text] [Related]
17. Schizophrenia: what's under the microscope? Taber KH; Lewis DA; Hurley RA J Neuropsychiatry Clin Neurosci; 2001; 13(1):1-4. PubMed ID: 11207324 [No Abstract] [Full Text] [Related]
18. Dose selection and comparator drugs in schizophrenia research. Kane JM J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828 [TBL] [Abstract][Full Text] [Related]
19. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Pira L; Mongeau R; Pani L Eur J Pharmacol; 2004 Nov; 504(1-2):61-4. PubMed ID: 15507222 [TBL] [Abstract][Full Text] [Related]
20. Depot neuroleptics: side effects and safety. Marder SR J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]